title: Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells.
abstract: Interleukin-17 (IL-17), a potent pro-inflammatory cytokine, plays an active role in inflammation and cancer. Recently, we found that increased IL-17-producing cells correlate with poor survival and increased lymphangiogenesis in non-small-cell lung cancer (NSCLC), but the mechanism is unknown. Here, we show that IL-17 promotes lymphangiogenesis via inducing vascular endothelial growth factor-C (VEGF-C) production by lung cancer cells. We found that IL-17 receptor (IL-17R) is expressed on the surface of Lewis lung carcinoma (LLC) cells but not on lymphatic endothelial cells (LEC). Moreover, LEC chemotaxis and tube formation (measures of net lymphangiogenic potential) were increased by conditioned medium from recombinant mouse IL-17 (rmIL-17)-stimulated LLC but not by rmIL-17. Interleukin-17 increased production of VEGF-C in lung cancer cell lines. The enhanced chemotaxis and endothelial cord formation in the presence of LLC/rmIL-17 was inhibited by addition of recombinant mouse VEGF R3/Fc chimera. Treatment of the A549 cells with rIL-17 significantly increased VEGF-C expression, which was extracellular signal-regulated protein kinase 1/2 (ERK 1/2) dependent. Importantly, we found significant correlations between IL-17 expression, VEGF-C expression and lymphatic vascular density (LVD) in NSCLC. We conclude that IL-17 is involved in lymphangiogenesis in NSCLC by enhancing production of VEGF-C, and IL-17 may be an important target for the treatment of NSCLC.
authors.affiliation: Institute of Cancer Institute of Respiratory Diseases Department of Pathology, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Chen
authors.forename: Qichao
authors.initials: Q
authors.lastname: Xie
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Cheng
authors.forename: Xinwei
authors.initials: X
authors.lastname: Diao
authors.forename: Yue
authors.initials: Y
authors.lastname: Cheng
authors.forename: Jiankun
authors.initials: J
authors.lastname: Liu
authors.forename: Wei
authors.initials: W
authors.lastname: Xie
authors.forename: Zhengtang
authors.initials: Z
authors.lastname: Chen
authors.forename: Bo
authors.initials: B
authors.lastname: Zhu
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002633:Chemotaxis / Q000187:drug effects; D017077:Culture Media, Conditioned / Q000494:pharmacology; D003593:Cytoplasm / Q000378:metabolism; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D020381:Interleukin-17 / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D042583:Lymphangiogenesis; D051379:Mice; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D053722:Receptors, Interleukin-17 / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D042582:Vascular Endothelial Growth Factor C / Q000235:genetics / Q000378:metabolism
chemical_list: D017077:Culture Media, Conditioned; D020381:Interleukin-17; D053722:Receptors, Interleukin-17; D011994:Recombinant Proteins; D042582:Vascular Endothelial Growth Factor C; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3
references.citation: Biochem Biophys Res Commun. 2008 Dec 19;377(3):826-31
references.pmid: 18951870
references.citation: Pharmacology. 2008;82(2):148-55
references.pmid: 18667841
references.citation: Nat Immunol. 2005 Nov;6(11):1133-41
references.pmid: 16200068
references.citation: J Hepatol. 2009 May;50(5):980-9
references.pmid: 19329213
references.citation: Semin Diagn Pathol. 1993 Nov;10(4):302-13
references.pmid: 7511250
references.citation: Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15505-10
references.pmid: 18832156
references.citation: Biochem Biophys Res Commun. 2001 Apr 6;282(3):735-8
references.pmid: 11401524
references.citation: Immunity. 1995 Dec;3(6):811-21
references.pmid: 8777726
references.citation: J Immunol. 2005 Nov 1;175(9):6177-89
references.pmid: 16237115
references.citation: Pharmacology. 2007;80(4):207-18
references.pmid: 17622766
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Osteoarthritis Cartilage. 2006 Apr;14(4):345-52
references.pmid: 16311048
references.citation: Blood. 2007 Feb 1;109(3):1010-7
references.pmid: 17032920
references.citation: Blood. 2003 Apr 1;101(7):2620-7
references.pmid: 12411307
references.citation: Osteoarthritis Cartilage. 2004 Sep;12(9):683-91
references.pmid: 15325633
references.citation: Lung Cancer. 2010 Sep;69(3):348-54
references.pmid: 20022135
references.citation: Biochem Biophys Res Commun. 2006 Sep 8;347(4):852-8
references.pmid: 16859642
references.citation: Lung Cancer. 2007 Nov;58(2):205-13
references.pmid: 17686546
references.citation: J Immunol. 2009 Oct 1;183(7):4169-75
references.pmid: 19767566
references.citation: Development. 1996 Dec;122(12):3829-37
references.pmid: 9012504
references.citation: Semin Surg Oncol. 2003;21(2):128-37
references.pmid: 14508863
references.citation: Immunity. 2004 Oct;21(4):467-76
references.pmid: 15485625
references.citation: Infect Immun. 2004 Sep;72(9):5019-26
references.pmid: 15321994
references.citation: Am J Physiol Lung Cell Mol Physiol. 2005 Aug;289(2):L268-73
references.pmid: 16003000
references.citation: J Biol Chem. 1998 Apr 3;273(14):8413-8
references.pmid: 9525952
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7344-53
references.pmid: 16243806